|
Press Releases |
|
 |
|
Friday, November 27, 2020 |
|
雅各臣公布二零二一财年中期业绩 |
从事非专利药及品牌药品研发、生产、市场推广及销售的领先企业─雅各臣科研制药有限公司(「雅各臣」或「集团」;股份代号:2633)今天公布公司及其附属公司(统称「集团」)于截至二零二零年九月三十日止六个月(「报告期」)的中期业绩。 more info >> |
|
雅各臣公佈二零二一財年中期業績 |
從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業─雅各臣科研製藥有限公司(「雅各臣」或「集團」;股份代號:2633)今天公佈公司及其附屬公司(統稱「集團」)於截至二零二零年九月三十日止六個月(「報告期」)的中期業績。 more info >> |
|
Jacobson Pharma Announces FY2021 Interim Results |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, today announced the interim results of the Company and its subsidiaries (collectively the "Group") for the six months ended 30 September 2020 (the "reporting period"). more info >> |
|
Wednesday, September 23, 2020 |
|
雅各臣就分拆品牌医疗保健业务递交上市申请表格(A1表格) |
于香港从事基要药物及品牌保健护理产品研发、生产、市场推广及销售的领先企业 ─ 雅各臣科研制药有限公司(「雅各臣」或「集团」;股份代号:2633)今天公布已就集团的附属公司健倍苗苗(保健)有限公司(「健倍苗苗」)的股份于在香港联合交易所有限公司(「香港联交所」)主板上市及买卖递交上市申请表格(A1表格)。 more info >> |
|
雅各臣就分拆品牌醫療保健業務遞交上市申請表格(A1表格) |
於香港從事基要藥物及品牌保健護理產品研發、生產、市場推廣及銷售的領先企業 ─ 雅各臣科研製藥有限公司(「雅各臣」或「集團」;股份代號:2633)今天公佈已就集團的附屬公司健倍苗苗(保健)有限公司(「健倍苗苗」)的股份於在香港聯合交易所有限公司(「香港聯交所」)主板上市及買賣遞交上市申請表格(A1表格)。 more info >> |
|
Jacobson Pharma Submits Form A1 to Spin-off Its Branded Healthcare Business |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or "the Group"; Stock Code: 2633.HK), a leading company engaged in the research, development, production, marketing and sale of essential medicines and branded healthcare products in Hong Kong more info >> |
|
Thursday, August 27, 2020 |
|
雅各臣与复星医药合作在香港和澳门供应潜在1,000万剂BioNTech SE 2019冠状病毒病在研疫苗 |
于香港从事基要药物及品牌保健护理产品研发、生产、市场推广及销售的领先企业 - 雅各臣科研制药有限公司(「雅各臣」或「集团」;股份代号:2633)今天公布 more info >> |
|
雅各臣與復星醫藥合作在香港和澳門供應潛在1,000萬劑BioNTech SE 2019冠狀病毒病在研疫苗 |
於香港從事基要藥物及品牌保健護理產品研發、生產、市場推廣及銷售的領先企業 ─ 雅各臣科研製藥有限公司(「雅各臣」或「集團」;股份代號:2633)今天公佈 more info >> |
|
Jacobson Pharma Collaborates with Fosun Pharma Group to Supply Potentially 10 Million Doses of BioNTech SE's COVID-19 Vaccine Candidate in Hong Kong and Macau |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or "the Group"; Stock Code: 2633.HK), a leading company engaged in the research, development, production, marketing and sale of essential medicines and branded healthcare products in Hong Kong, today announced the signing of a letter of intent ("Letter of Intent") with Fosun Industrial Co. Ltd. more info >> |
|
Tuesday, June 30, 2020 |
|
雅各臣公佈二零二零財年全年業績 |
從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業─雅各臣科研製藥有限公司(「雅各臣」或「集團」;股份代號:2633)今天公佈公司及其附屬公司(統稱「集團」)於截至二零二零年三月三十一日止年度(「二零二零財年」或「報告期」)的全年業績。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
How Do AI Workflow Automations Work?
Aug 16, 2025 00:00 HKT/SGT
|
|
|
Everest Medicines' New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access
Aug 15, 2025 23:18 HKT/SGT
|
|
|
Yuexiu REIT Maintains Overall Operational Stability, Achieves Revenue of Over RMB966 Million
Aug 15, 2025 23:17 HKT/SGT
|
|
|
The 35th Food Expo opens today
Aug 15, 2025 23:16 HKT/SGT
|
|
|
Shoucheng Joins World Humanoid Robot Games - 88 Spectators Invited
Aug 15, 2025 23:06 HKT/SGT
|
|
|
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC
Aug 15, 2025 20:15 HKT/SGT
|
|
|
艾曲莫德入選《2025 ACG臨床指南:成人潰瘍性結腸炎》,獲強烈推薦用於中重度潰瘍性結腸炎的誘導緩解及維持緩解治療
Aug 15, 2025 20:07 HKT/SGT
|
|
|
艾曲莫德入选《2025 ACG临床指南:成人溃疡性结肠炎》,获强烈推荐用于中重度溃疡性结肠炎的诱导缓解及维持缓解治疗
Aug 15, 2025 19:56 HKT/SGT
|
|
|
OrbusNeich Records Growth in 2025 Interim Results, Revenue and Net Profit Reach US$83.6 Million and US$19.8 Million Respectively
Aug 15, 2025 19:11 HKT/SGT
|
|
|
業聚醫療2025年中期業績收入及純利雙雙增長 分別達8,360萬美元及1,980萬美元
Aug 15, 2025 18:53 HKT/SGT
|
|
|
业聚医疗2025年中期业绩收入及纯利双双增长 分别达8,360万美元及1,980万美元
Aug 15, 2025 18:10 HKT/SGT
|
|
|
RAK ICC Strengthens Foundations Regime with 2025 Legislative Enhancements
Aug 15, 2025 18:00 HKT/SGT
|
|
|
廣發証券榮膺國家數據管理能力成熟度(DCMM)最高等級認証
Aug 15, 2025 17:28 HKT/SGT
|
|
|
米国株式アクティブ残高10年連続世界No.1ティー・ロウ・プライス[1] 日本法人が既存追加型株式投資信託に「毎月決算・予想分配金提示型」ファンドを新規設定
Aug 15, 2025 17:15: JST
|
|
|
广发证券荣膺国家数据管理能力成熟度(DCMM)最高等级认证
Aug 15, 2025 17:12 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|